

BLA 761148

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Assertio Specialty Pharmaceuticals, LLC
Attention: Ryan Langner
Associate Director, Operations
100 S. Saunders Road Suite 300
Lake Forest, Illinois 60045

Dear Ryan Langner:

Please refer to your biologic license application (BLA) submitted under section 351 of the Public Health Service Act for Rolvedon (eflapegrastim-xnst) injection, which was licensed on September 9, 2022.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for the following PMR which was deferred until the date listed:

PMR 3891-2: Deferred until June 30, 2026.

Therefore, we are hereby notifying you that due to your failure to submit either a pediatric assessment or a request for a deferral extension, you are not in compliance with federal law.

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355c(d)(1)], you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a **"DEFERRAL EXTENSION REQUESTED"** in your response.

In accordance with the FD&C Act, FDA will post this letter and your response to the website at <https://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a **"RESPONSE TO PREA NON-COMPLIANCE LETTER."** To facilitate our review, submit this information to your BLA

with a cross-reference letter to the investigational new drug application (IND) to which your protocol has been submitted.

If you have any questions, please contact Rolanda Bailey, Regulatory Project Manager, at 240-402-5631 or email at rolanda.bailey@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tanya Wroblewski, MD
Division Director
Division of Nonmalignant Hematology
Office of Cardiology, Hematology, Endocrinology,
and Nephrology
Office of New Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ROSANNA W SETSE
07/27/2026 08:57:54 AM
Signed on behalf of Dr Tanya Wroblewski.